Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer: Development and Validation of a Clinical-Inflammatory Nomogram.
3/5 보강
TL;DR
Age ≥ 50 years, HER2 IHC3+, dual HER2 blockade, and high PLR independently predict pCR in patients with HER2+ breast cancer, and the nomogram provides a clinically applicable tool for pCR prediction, which may aid in optimizing personalized NAC strategies for this population.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
460 patients with HER2+ breast cancer who received NAC at Nanchang People's Hospital (January 2017-May 2025).
I · Intervention 중재 / 시술
NAC at Nanchang People's Hospital (January 2017-May 2025)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Age ≥ 50 years, HER2 IHC3+, dual HER2 blockade, and high PLR independently predict pCR in patients with HER2+ breast cancer. The nomogram provides a clinically applicable tool for pCR prediction, which may aid in optimizing personalized NAC strategies for this population.
OpenAlex 토픽 ·
Breast Cancer Treatment Studies
HER2/EGFR in Cancer Research
Advanced Breast Cancer Therapies
Age ≥ 50 years, HER2 IHC3+, dual HER2 blockade, and high PLR independently predict pCR in patients with HER2+ breast cancer, and the nomogram provides a clinically applicable tool for pCR prediction,
- p-value P < 0.05
- p-value p < 0.05
APA
Xiaoliu Jiang, Zhaohui Huang, et al. (2026). Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer: Development and Validation of a Clinical-Inflammatory Nomogram.. Annals of surgical oncology, 33(5), 4530-4543. https://doi.org/10.1245/s10434-026-19178-z
MLA
Xiaoliu Jiang, et al.. "Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer: Development and Validation of a Clinical-Inflammatory Nomogram.." Annals of surgical oncology, vol. 33, no. 5, 2026, pp. 4530-4543.
PMID
41691084 ↗
Abstract 한글 요약
[BACKGROUND] Pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) predicts favorable prognosis in breast cancer. However, significant gaps remain in identifying reliable predictors of pCR. This study aimed to identify clinicopathological and inflammatory factors associated with pCR in HER2 + breast cancer and develop a predictive nomogram.
[PATIENTS AND METHODS] We retrospectively analyzed 460 patients with HER2+ breast cancer who received NAC at Nanchang People's Hospital (January 2017-May 2025). Patients were randomly allocated to the training or testing cohorts at a ratio of 7:3. Variables with significant associations in univariate analysis (P < 0.05) were included in multivariate logistic regression. A nomogram incorporating independent predictors was validated for its discrimination, calibration, and clinical utility.
[RESULTS] Overall pCR rate was 47.2% (217/460). Significantly higher pCR rates occurred with: age ≥ 50 years (53.4% versus < 50:38.7%), ER- (54.6% versus ER+: 39.1%), PR- (52.0% versus PR+: 36.2%), HER2 IHC3+ (51.9% versus IHC2+/FISH+: 26.2%), dual HER2 blockade (54.9% versus chemotherapy alone: 15.9%), and high platelet-to-lymphocyte ratio (PLR) (61.0% versus low: 45.1%) (all p < 0.05). Univariate analysis in the training cohort identified that the aforementioned variables were significant predictors. Multivariate analysis confirmed age ≥ 50 years, HER2 IHC3+, dual HER2 blockade, and high PLR as independent predictors. The nomogram demonstrated good discrimination (training AUC = 0.736; testing AUC = 0.689), satisfactory calibration and favorable clinical net benefit.
[CONCLUSIONS] Age ≥ 50 years, HER2 IHC3+, dual HER2 blockade, and high PLR independently predict pCR in patients with HER2+ breast cancer. The nomogram provides a clinically applicable tool for pCR prediction, which may aid in optimizing personalized NAC strategies for this population.
[PATIENTS AND METHODS] We retrospectively analyzed 460 patients with HER2+ breast cancer who received NAC at Nanchang People's Hospital (January 2017-May 2025). Patients were randomly allocated to the training or testing cohorts at a ratio of 7:3. Variables with significant associations in univariate analysis (P < 0.05) were included in multivariate logistic regression. A nomogram incorporating independent predictors was validated for its discrimination, calibration, and clinical utility.
[RESULTS] Overall pCR rate was 47.2% (217/460). Significantly higher pCR rates occurred with: age ≥ 50 years (53.4% versus < 50:38.7%), ER- (54.6% versus ER+: 39.1%), PR- (52.0% versus PR+: 36.2%), HER2 IHC3+ (51.9% versus IHC2+/FISH+: 26.2%), dual HER2 blockade (54.9% versus chemotherapy alone: 15.9%), and high platelet-to-lymphocyte ratio (PLR) (61.0% versus low: 45.1%) (all p < 0.05). Univariate analysis in the training cohort identified that the aforementioned variables were significant predictors. Multivariate analysis confirmed age ≥ 50 years, HER2 IHC3+, dual HER2 blockade, and high PLR as independent predictors. The nomogram demonstrated good discrimination (training AUC = 0.736; testing AUC = 0.689), satisfactory calibration and favorable clinical net benefit.
[CONCLUSIONS] Age ≥ 50 years, HER2 IHC3+, dual HER2 blockade, and high PLR independently predict pCR in patients with HER2+ breast cancer. The nomogram provides a clinically applicable tool for pCR prediction, which may aid in optimizing personalized NAC strategies for this population.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Female
- Nomograms
- Neoadjuvant Therapy
- Breast Neoplasms
- Erb-b2 Receptor Tyrosine Kinases
- Middle Aged
- Retrospective Studies
- Antineoplastic Combined Chemotherapy Protocols
- Prognosis
- Adult
- Follow-Up Studies
- Aged
- Chemotherapy
- Adjuvant
- Biomarkers
- Tumor
- Inflammation
- Breast cancer
- Inflammatory biomarkers
- Neoadjuvant chemotherapy
- Nomogram
- Pathological complete response
같은 제1저자의 인용 많은 논문 (5)
- FASN at the crossroads of tumor metabolism, immune evasion, and therapy resistance: Mechanistic insights and therapeutic opportunities.
- Association of gastroesophageal reflux disease with the incidence of multiple cancers: a systematic review and meta-analysis.
- Single-cell RNA sequencing and spatial transcriptomic analysis reveal a distinct population of G6PD cells with aberrant bile acid metabolism in hepatocellular carcinoma.
- ASO Visual Abstract: Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer-Development and Validation of a Clinical-Inflammatory Nomogram.
- miRNA-HK2 networks in cancer metabolism: Mechanisms and dual-targeting therapeutic opportunities.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.